Secondary analysis of ARASENS in metastatic hormone-sensitive prostate cancer: darolutamide + ADT + docetaxel vs placebo + ADT + docetaxel added 6.3 months of Q-TWiST over 53 months (p<0.001; relative gain 16.0%), but time with grade 3/4 toxicity was longer (17.2 vs 11.3 months).
Secondary analysis
Maiorano et al. Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer from the ARASENS trial